ElevateBio Raises $525m To Expand Cell And Gene Therapy Expertise
Executive Summary
With $845m raised to date, ElevateBio will keep building its cell and gene therapy manufacturing capabilities and continue creating new companies and partnerships, but with a global focus.
You may also be interested in...
AlloVir Gains Third RMAT Designation For Antiviral T Cell Therapy
Gaining the special regulatory status in a prophylactic setting for posoleucel is the most significant yet for the T cell therapy developer.
Finance Watch: A Summer Slowdown? Not For Venture Capital Mega-Rounds
Private Company Edition: The latest $100m-plus VC financings include $112.5m for PepGen, Deep Genomics’ $180m series C round and a $166m series D for Rakuten Medical. Also, Lumira Ventures raised a $220m fourth fund and will manage a separate $35m fund backed by Angelini Pharma.
Finance Watch: Insilico Raises $255m To Take AI-Discovered Drugs Into The Clinic
Private Company Edition: Nine new venture capital mega-rounds include Insilico’s series C, $250m from Blackstone for a CAR-T therapy spinout from Intellia and a $210m series B round for Umoja.